Zobrazeno 1 - 10
of 2 233
pro vyhledávání: '"THORACIC RADIOTHERAPY"'
Autor:
Wenxia Li, Peiye Wu, Zhanpeng Liang, Luzhen Li, Yunqi Chen, Wenjing Zhang, Huatang Zhang, Cantu Fang
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Tyrosine Kinase Inhibitors (TKIs) is an important therapy for patients with oncogene-mutated Non-Small Cell Lung Cancer (NSCLC). However, acquired resistance remains a major challenge. The efficacy of TKIs plus thoracic radiothera
Externí odkaz:
https://doaj.org/article/3b0a7ed8e40047c5afd33b90b399f7bc
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Background First-line chemotherapy combined with bevacizumab is one of the standard treatment modes for patients with advanced non-small cell lung cancer (NSCLC). Thoracic radiotherapy (TRT) can provide significant local control and survival
Externí odkaz:
https://doaj.org/article/a5dd2aa2028f4dcb9ad6cd1b21698c8b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiaoli Mu, Yixin Zhou, Qing Liu, Jiantao Wang, Feng Xu, Feng Luo, Ke Wang, Lu Li, Panwen Tian, Yalun Li, Jiewei Liu, Yan Zhang, Jiyan Liu, Yan Li
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first‐line immunotherapy and chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC) remains unclear. We sought to elucidate th
Externí odkaz:
https://doaj.org/article/ddb9d6bc634c47bbaef54d5260f49207
Autor:
Gustav Graabak, MD, Bjørn Henning Grønberg, MD, PhD, Kristin Toftaker Killingberg, MD, PhD, Tarje Onsøien Halvorsen, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100688- (2024)
Introduction: 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) is recommended for staging and defining target volume in limited-stage SCLC, though the impact on outcomes compared with CT staging and elective nodal irra
Externí odkaz:
https://doaj.org/article/fd5d36ffc1bf4dbea2c16052530f08aa
Publikováno v:
Precision Radiation Oncology, Vol 8, Iss 1, Pp 14-21 (2024)
Abstract Objective This study assessed the outcomes of elderly patients with limited‐stage small cell lung cancer (LS‐SCLC), which may be linked to the timing of thoracic radiotherapy (TRT) following chemotherapy. Methods Elderly patients (n = 78
Externí odkaz:
https://doaj.org/article/0e88ca92ff53400488f4cd231765a1fe
Publikováno v:
Thoracic Cancer, Vol 15, Iss 8, Pp 642-653 (2024)
Abstract Background The optimal timing of thoracic radiotherapy (TRT) in driver‐gene‐negative metastatic non‐small cell lung cancer (mNSCLC) patients was retrospectively investigated based on survival and safety profile. Methods The efficacy an
Externí odkaz:
https://doaj.org/article/92c5347463484f8ba6b483c5cc69968b
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The superior efficacy of concurrent thoracic radiotherapy (TRT) and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been proven in locally advanced and advanced non-small cell lung cancer (NSCLC) patien
Externí odkaz:
https://doaj.org/article/a9a80b661d1749b4afd4b2693bfc1fed
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Platinum-etoposide chemotherapy combined with immune checkpoint inhibitors (ICIs) has been recommended as the first-line standard treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, the effect of thoracic radi
Externí odkaz:
https://doaj.org/article/d7eb242346904cc3a33934f4af582653
Autor:
Boyu Qin, Lingli Xin, Chen Liang, Lingling Li, Qi Song, Yaping Long, Xiaoling Zhang, Dan Wang, Weiwei Shi, Jing Zhang, Yi Hu, Bo Yang, Qi Xiong
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-lin
Externí odkaz:
https://doaj.org/article/7c106376a8694d80aca4be66c8ba0624